BLK vs LAB · P/E 27, rev $24.22B vs rev $174.4M
BlackRock Inc (BLK) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
BLK currently screens at market cap $172.19B and trailing P/E 26.6. LAB currently screens at market cap $317.1M.
Not investment advice. Open the BLK and LAB stock pages for the full models.
Not investment advice.